Pregabalin

Generic Name: Pregabalin

Brand Names: Lyrica, Pregabalin Accord, Pregabalin Pfizer, Pregabalin Sandoz, Pregabalin Mylan, Pregabalin Zentiva

Drug Type: Small Molecule

Chemical Formula: C_₈H_₁₇NO_₂

CAS Number: 148553-50-8

Unique Ingredient Identifier: 55JG375S6M

Background: Pregabalin is structurally similar to gamma-aminobutyric acid (GABA) - an inhibitory neurotransmitter. It may be used to manage neuropathic pain, postherpetic neuralgia, and fibromyalgia among other conditions. Although as per the FDA Label the mechanism of action has not been definitively defined, there is evidence that pregabalin exerts its effects by bind...

Indication: Pregabalin is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, neuropathic pain associated with spinal cord injury, and as adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older.

Associated Conditions: Diabetic Peripheral Neuropathic Pain (DPN), Epilepsies, Fibromyalgia, Generalized Anxiety Disorder, Neuropathic Pain, Partial-Onset Seizures, Peripheral Neuropathic Pain, Peripheral neuropathy, Postherpetic Neuralgia

Associated Therapies: -

Clinical Trials

Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease

Not Applicable

Conditions: Peripheral Arterial Disease

Interventions: Dietary Supplement: Fructose
Dietary Supplement: Magnesium oxide
Drug: Oxycodone
Drug: Pregabalin

First Posted Date: 2015-05-28

Last Posted Date: 2015-05-28

Lead Sponsor: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

Target Recruit Count: 150

Registration Number: NCT02455726

Abuse Liability of Pregabalin and Its Effects on Benzodiazepine Withdrawal Symptoms

Phase 4

Terminated

Conditions: Substance-Related Disorders

Interventions: Drug: Pregabalin
Drug: Placebo

First Posted Date: 2015-04-22

Last Posted Date: 2016-03-23

Lead Sponsor: Centre for Addiction and Mental Health

Target Recruit Count: 1

Registration Number: NCT02423018

Locations: 🇨🇦
Centre for Addiction and Mental Health, Toronto, Ontario, Canada

A Study of Duloxetine (LY248686) in Participants With Diabetic Peripheral Neuropathic Pain (DPNP)

Phase 4

Completed

Conditions: Diabetic Peripheral Neuropathic Pain

Interventions: Drug: Duloxetine
Drug: Pregabalin
Drug: Placebo

First Posted Date: 2015-04-16

Last Posted Date: 2019-09-18

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 304

Registration Number: NCT02417935

Pregabalin in CIPN

Not Applicable

Completed

Conditions: Neuropathy
Pain

Interventions: Drug: Pregabalin
Drug: Placebo

First Posted Date: 2015-03-20

Last Posted Date: 2019-05-14

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 26

Registration Number: NCT02394951

Locations: 🇺🇸
Washington University School of Medicine/Barnes Jewish Hospital, Saint Louis, Missouri, United States

Pharmacovigilance in Gerontopsychiatric Patients

Phase 3

Terminated

Conditions: Dementia
Depression
Schizophrenia
Psychosomatic Disorders
Anxiety Disorders

Interventions: Drug: Phenobarbital
Drug: Phenytoin
Drug: Carbamazepine
Drug: Oxcarbazepine
Drug: Valproic Acid
Drug: Lamotrigine
Drug: Topiramate
Drug: Gabapentin
Drug: Levetiracetam
Drug: Pregabalin
Drug: Lacosamide
Drug: Clonazepam
Drug: Biperiden
Drug: Levomepromazine
Drug: Fluphenazine
Drug: Perphenazine
Drug: Perazine
Drug: Thioridazine
Drug: Haloperidol
Drug: Melperone
Drug: Pipamperone
Drug: Bromperidol
Drug: Benperidol
Drug: Sertindole
Drug: Ziprasidone
Drug: Flupentixol
Drug: Chlorprothixene
Drug: Zuclopenthixol
Drug: Fluspirilene
Drug: Pimozide
Drug: Clozapine
Drug: Olanzapine
Drug: Quetiapine
Drug: Sulpiride
Drug: Tiapride
Drug: Amisulpride
Drug: Prothipendyl
Drug: Risperidone
Drug: Aripiprazole
Drug: Paliperidone
Drug: Diazepam
Drug: Oxazepam
Drug: Lorazepam
Drug: Bromazepam
Drug: Clobazam
Drug: Alprazolam
Drug: Hydroxyzine
Drug: Buspirone
Drug: Chloral Hydrate
Drug: Flurazepam
Drug: Nitrazepam
Drug: Triazolam
Drug: Lormetazepam
Drug: Temazepam
Drug: Midazolam
Drug: Brotizolam
Drug: Zopiclone
Drug: Zolpidem
Drug: Zaleplon
Drug: Melatonin
Drug: Clomethiazole
Drug: Diphenhydramine
Drug: Promethazine
Drug: Imipramine
Drug: Clomipramine
Drug: Opipramol
Drug: Trimipramine
Drug: Amitriptyline
Drug: Nortriptyline
Drug: Doxepin
Drug: Maprotiline
Drug: Amitriptyline oxide
Drug: Fluoxetine
Drug: Citalopram
Drug: Paroxetine
Drug: Sertraline
Drug: Fluvoxamine
Drug: Escitalopram
Drug: Tranylcypromine
Drug: Moclobemide
Drug: Mianserin
Drug: Trazodone
Drug: Mirtazapine
Drug: Bupropion
Drug: Venlafaxine
Drug: Reboxetine
Drug: Duloxetine
Drug: Agomelatine
Drug: Pyritinol
Drug: Piracetam
Drug: Donepezil
Drug: Rivastigmine
Drug: Galantamine
Drug: Memantine
Drug: Nicergoline
Drug: Acamprosate
Drug: Lithium

First Posted Date: 2015-03-02

Last Posted Date: 2018-02-28

Lead Sponsor: Hannover Medical School

Target Recruit Count: 407

Registration Number: NCT02374567

Locations: 🇩🇪
Bezirkskrankenhaus Augsburg, Augsburg, Germany
🇩🇪
Krankenhaus Hedwigshöhe, Berlin, Germany
🇩🇪
Hannover Medical School, Hannover, Germany

and more 2 locations

Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy

Phase 2

Terminated

Conditions: Painful Diabetic Peripheral Neuropathy (PDPN)

Interventions: Drug: pregabalin
Drug: ASP3662 placebo
Drug: ASP3662
Drug: pregabalin placebo

First Posted Date: 2015-02-26

Last Posted Date: 2019-03-26

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 115

Registration Number: NCT02372578

Locations: 🇺🇸
Site US10013, Kettering, Ohio, United States
🇺🇸
Site US10039, Phoenix, Arizona, United States
🇺🇸
Site US10051, Boston, Massachusetts, United States

and more 34 locations

Pre-operative Pregabalin and Ketamine to Prevent Phantom Pain

Phase 3

Withdrawn

Conditions: Phantom Pain

Interventions: Drug: Placebo
Drug: Pregabalin
Drug: Ketamine

First Posted Date: 2014-12-08

Last Posted Date: 2018-12-19

Lead Sponsor: University of Texas Southwestern Medical Center

Registration Number: NCT02311777

Locations: 🇺🇸
UTSW, Parkland Hospital, Dallas, Texas, United States
🇺🇸
Parkland Health Hospital System, Dallas, Texas, United States

Effect of Pregabalin on Post Operative Pain in Abdominal Hysterectomy Under Spinal Anesthesia With Intrathecal Morphine

Phase 4

Completed

Conditions: Post Operative Pain

Interventions: Drug: placebo
Drug: Pregabalin

First Posted Date: 2014-11-06

Last Posted Date: 2019-03-15

Lead Sponsor: Mahidol University

Target Recruit Count: 125

Registration Number: NCT02285010

Locations: 🇹🇭
Faculty of Medicine Siriraj Hospital, Bangkoknoi, Bangkok, Thailand

Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations

Phase 4

Completed

Conditions: Cryptogenic Sensory Polyneuropathy

Interventions: Drug: Nortriptyline
Drug: Mexiletine
Drug: Duloxetine
Drug: Pregabalin

First Posted Date: 2014-10-09

Last Posted Date: 2018-07-06

Lead Sponsor: University of Kansas Medical Center

Target Recruit Count: 402

Registration Number: NCT02260388

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
University of Miami Miller School of Medicine, Miami, Florida, United States
🇺🇸
Indiana University, Indianapolis, Indiana, United States

and more 43 locations

Assessment of the Analgesic Effects of PF-06273340 in Healthy Volunteers Using Evoked Pain Endpoints

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Pregabalin
Drug: Placebo
Drug: PF-06273340
Drug: Ibuprofen

First Posted Date: 2014-10-09

Last Posted Date: 2015-02-04

Lead Sponsor: Pfizer

Target Recruit Count: 20

Registration Number: NCT02260947

Locations: 🇳🇱
Centre for Human Drug Research, Leiden, CL, Netherlands

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy